Current Issue : July - September Volume : 2020 Issue Number : 3 Articles : 5 Articles
Abstract: PB10 IgG1, a monoclonal antibody (MAb) directed against an immunodominant epitope\non the enzymatic subunit (RTA) of ricin toxin (RT), has been shown to passively protect mice\nand non-human primates from an aerosolized lethal-dose RT challenge. However, it was\nrecently demonstrated that the therapeutic efficacy of PB10 IgG1 is significantly improved when\nco-administered with a second MAb, SylH3, targeting RTâ??s binding subunit (RTB). Here we report that\nthe PB10/SylH3 cocktail is also superior to PB10 alone when used as a pre-exposure prophylactic (PrEP)\nin a mouse model of intranasal RT challenge. The benefit of the PB10/SylH3 cocktail prompted us to\nengineer a humanized IgG1 version of SylH3 (huSylH3). The huPB10/huSylH3 cocktail proved highly\nefficacious in the mouse model, thereby opening the door to future testing in non-human primates....
Background: ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity\nand pharmacokinetic equivalence between the two have been previously demonstrated. Here we report results\nfrom a comparative clinical study that evaluated the efficacy and safety of ABP 710 relative to the RP in patients\nwith rheumatoid arthritis (RA).\nMethods: In this multicenter, randomized, double-blind, 50-week equivalence study, patients with moderate to\nsevere active RA despite methotrexate received 3-mg/kg infusions of ABP 710 or RP at predetermined intervals\nbased on initial randomization and then with re-randomization at week 22. The primary endpoint was response\ndifference (RD) of ACR20 at week 22, with clinical equivalence evaluated based on................
Efforts to express human therapeutic proteins in photosynthetic organisms have\nbeen described in the literature. Regarding microalgae, most of the research\nentailed a heterologous transformation of the chloroplast, but transformant cells\nfailed to accumulate the desired recombinant proteins in high quantity. The present\nwork provides methods and DNA construct formulations for over-expressing in\nphotosynthetic cyanobacteria, at the protein level, human-origin bio-pharmaceutical\nand bio-therapeutic proteins. Proof-of-concept evidence is provided for the design and\nreduction to practice of â??fusion constructs as protein overexpression vectorsâ? for the\ngeneration of the bio-therapeutic protein interferon alpha-2 (IFN). IFN is a member of\nthe Type I interferon cytokine family, well-known for its antiviral and anti-proliferative\nfunctions. Fusion construct formulations enabled accumulation of IFN up to 12% of\ntotal cellular protein in soluble form. In addition, the work reports on the isolation and\npurification of the fusion IFN protein and preliminary verification of its antiviral activity.\nCombining the expression and purification protocols developed here, it is possible to\nproduce fairly large quantities of interferon in these photosynthetic microorganisms,\ngenerated from sunlight, CO2, and H2O....
Abstract: Novel Coronavirus (2019-nCoV) is an emerging pathogen that was first identified inWuhan,\nChina in late December 2019. This virus is responsible for the ongoing outbreak that causes severe\nrespiratory illness and pneumonia-like infection in humans. Due to the increasing number of cases\nin China and outside China, the WHO declared coronavirus as a global health emergency. Nearly\n35,000 cases were reported and at least 24 other countries or territories have reported coronavirus\ncases as early on as February. Inter-human transmission was reported in a few countries, including\nthe United States. Neither an effective anti-viral nor a vaccine is currently available to treat this\ninfection. As the virus is a newly emerging pathogen, many questions remain unanswered regarding\nthe virusâ??s reservoirs, pathogenesis, transmissibility, and much more is unknown. The collaborative\nefforts of researchers are needed to fill the knowledge gaps about this new virus, to develop the\nproper diagnostic tools, and effective treatment to combat this infection. Recent advancements in\nplant biotechnology proved that plants have the ability to produce vaccines or biopharmaceuticals\nrapidly in a short time. In this review, the outbreak of 2019-nCoV in China, the need for rapid vaccine\ndevelopment, and the potential of a plant system for biopharmaceutical development are discussed....
Abstract: Delivery of therapeutic agents into the brain is a major challenge in central nervous\nsystem drug development. The blood-brain barrier (BBB) prevents access of biotherapeutics to\ntheir targets in the central nervous system and, therefore, prohibits the effective treatment of many\nneurological disorders. To find blood-brain barrier shuttle peptides that could target therapeutics\nto the brain, we applied a phage display technology on a primary endothelial rat cellular model.\nTwo identified peptides from a 12 mer phage library, GLHTSATNLYLH and VAARTGEIYVPW,\nwere selected and their permeability was validated using the in vitro BBB model. The permeability\nof peptides through the BBB was measured by ultra-performance liquid chromatography-tandem\nmass spectrometry coupled to a triple-quadrupole mass spectrometer (UHPLC-MS/MS). We showed\nhigher permeability for both peptides compared to N-C reversed-sequence peptides through in vitro\nBBB: for peptide GLHTSATNLYLH 3.3*10-7 cm/s and for peptide VAARTGEIYVPW 1.5*10-6\ncm/s. The results indicate that the peptides identified by the in vitro phage display technology could\nserve as transporters for the administration of biopharmaceuticals into the brain. Our results also\ndemonstrated the importance of proper BBB model for the discovery of shuttle peptides through\nphage display libraries....
Loading....